Susquehanna International Group
IBRX icon

Susquehanna International Group’s ImmunityBio IBRX Stock Holding History

Susquehanna International Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.1M Buy
1,833,400
+381,500
+26% +$2.61M ﹤0.01% 2639
2025
Q4 		$2.87M Buy
1,451,900
+139,200
+11% +$315K ﹤0.01% 4951
2025
Q3 		$3.23M Buy
1,312,700
+434,800
+50% +$1.12M ﹤0.01% 4837
2025
Q2 		$2.32M Buy
877,900
+90,800
+12% +$244K ﹤0.01% 5481
2025
Q1 		$2.37M Buy
787,100
+378,600
+93% +$1.15M ﹤0.01% 5161
2024
Q4 		$1.05M Buy
408,500
+21,400
+6% +$89.1K ﹤0.01% 6839
2024
Q3 		$1.44M Sell
387,100
-248,900
-39% -$1.15M ﹤0.01% 6003
2024
Q2 		$4.02M Buy
636,000
+125,100
+24% +$825K ﹤0.01% 3806
2024
Q1 		$2.74M Buy
510,900
+439,100
+612% +$1.99M ﹤0.01% 4683
2023
Q4 		$360K Sell
71,800
-330,800
-82% -$1.04M ﹤0.01% 9432
2023
Q3 		$680K Buy
402,600
+82,200
+26% +$165K ﹤0.01% 7509
2023
Q2 		$891K Buy
320,400
+126,300
+65% +$357K ﹤0.01% 6966
2023
Q1 		$353K Sell
194,100
-127,300
-40% -$396K ﹤0.01% 9354
2022
Q4 		$1.63M Sell
321,400
-10,900
-3% -$59.9K ﹤0.01% 5106
2022
Q3 		$1.65M Sell
332,300
-27,300
-8% -$124K ﹤0.01% 5354
2022
Q2 		$1.34M Sell
359,600
-33,500
-9% -$135K ﹤0.01% 5820
2022
Q1 		$2.21M Sell
393,100
-256,900
-40% -$1.58M ﹤0.01% 5261
2021
Q4 		$3.95M Sell
650,000
-137,100
-17% -$1.03M ﹤0.01% 4145
2021
Q3 		$7.67M Sell
787,100
-18,800
-2% -$207K ﹤0.01% 3268
2021
Q2 		$11.5M Sell
805,900
-185,700
-19% -$3.07M ﹤0.01% 2721
2021
Q1 		$23.5M Buy
991,600
+108,700
+12% +$2.82M ﹤0.01% 1701
2020
Q4 		$11.8M Buy
882,900
+407,100
+86% +$3.92M ﹤0.01% 2304
2020
Q3 		$3.3M Buy
475,800
+184,700
+63% +$1.84M ﹤0.01% 3701
2020
Q2 		$3.58M Buy
291,100
+231,000
+384% +$1.3M ﹤0.01% 3506
2020
Q1 		$173K Buy
+60,100
New +$301K ﹤0.01% 8859
2019
Q2 		– Sell
-11,100
Closed -$18K – 10485
2019
Q1 		$18K Buy
+11,100
New +$13.9K ﹤0.01% 8599
2017
Q4 		– Sell
-23,400
Closed -$128K – 9536
2017
Q3 		$128K Sell
23,400
-24,800
-51% -$153K ﹤0.01% 8267
2017
Q2 		$366K Buy
+48,200
New +$208K ﹤0.01% 7220
2017
Q1 		– Sell
-13,500
Closed -$77K – 9381
2016
Q4 		$77K Sell
13,500
-18,700
-58% -$125K ﹤0.01% 9179
2016
Q3 		$251K Sell
32,200
-12,400
-28% -$92.6K ﹤0.01% 7215
2016
Q2 		$277K Buy
44,600
+17,700
+66% +$137K ﹤0.01% 7088
2016
Q1 		$221K Sell
26,900
-6,700
-20% -$63.1K ﹤0.01% 7805
2015
Q4 		$582K Sell
33,600
-31,000
-48% -$460K ﹤0.01% 6473
2015
Q3 		$740K Buy
+64,600
New +$1.41M ﹤0.01% 6336

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Susquehanna International Group's IBRX Position: Q1 2026 in Review

Susquehanna International Group reduced its ImmunityBio (IBRX) stake by 68% in Q1 2026, selling an estimated $16.9M and leaving 1,179,276 shares worth $9.05M. The position accounts for ﹤0.01% of the portfolio, ranked #3271.

Susquehanna International Group first reported a position in IBRX in Q3 2015 and has held it in 38 quarters since. The position peaked at $11.2M in Q1 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Susquehanna International Group held 1,179,276 shares of ImmunityBio worth $9.05M as of Q1 2026.
  • Susquehanna International Group sold 2,475,223 ImmunityBio shares in Q1 2026, an estimated $16.9M.
  • ImmunityBio made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3271 holding.
  • Susquehanna International Group first reported a position in ImmunityBio in Q3 2015 and has held it in 38 quarters since.
  • Susquehanna International Group's ImmunityBio position peaked at $11.2M in Q1 2021.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.